Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 8.00
Ask: 8.48
Change: -0.10 (-1.23%)
Spread: 0.48 (6.00%)
Open: 8.20
High: 8.20
Low: 8.00
Prev. Close: 8.10
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EpiSwitch used in diagnosis of canine lymphoma

15 Jan 2020 14:15

RNS Number : 9235Z
Oxford BioDynamics PLC
15 January 2020
 

15 January 2020

 

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics presents results of collaborative work demonstrating first proof of principle for EpiSwitch™ biomarkers in non-invasive diagnosis of canine lymphoma

 

·; Results of a study presented at the AACR Conference on Advances in Liquid Biopsies demonstrate the utility of EpiSwitch™ biomarkers for the diagnosis of canine lymphoma

·; Canine lymphoma accounts for 84% of blood cell malignancies and 24% of all tumours in dogs

 

Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, announces that a study focused on the diagnosis of B-cell lymphoma in dogs has been presented at the American Association for Cancer Research (AACR) Conference on Advances in Liquid Biopsies, which is taking place in Miami, Florida, 13-16 January 2020.

 

On Tuesday 14 January, OBD presented a paper/poster at the conference entitled: "Development and validation of diagnostic biomarkers for B-cell lymphoma using EpiSwitch™ profiling of whole blood: from humans to canines". The study was conducted in collaboration with the University of Minnesota Department of Veterinary Clinical Sciences, Animal Cancer Care and Research Program, College of Veterinary Medicine and Masonic Cancer Center.

 

OBD utilised its proprietary datasets of markers specific for regulatory 3D genome architecture of lymphoma in humans, as determined using EpiSwitch™, to see if these could be translated from humans into dogs. OBD was able to generate a new biomarker signature using whole blood from a cohort of dogs with lymphoma and validate it on a second cohort. This biomarker signature was able to correctly identify dogs with and without lymphoma with 80% accuracy, 80% sensitivity, 80% specificity, 80% positive predictive value and 80% negative predictive value.

 

The results of this study indicate that EpiSwitchbiomarkers can be successfully translated across species for related pathologies and conditions. This highlights the potential application of non-invasive EpiSwitch™ biomarkers in new therapeutic developments, including within the veterinary industry.

 

Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, said:

 

"Our EpiSwitchtechnology has provided us with a great wealth of data associated with lymphoma patients, and subsequently allowed us to translate these insights into canines, where there is a well-recognised unmet need. It is clear that the fundamentals of 3D genomics open up a new dimension for the application of EpiSwitch™, particularly in veterinary science and animal welfare.

 

Whilst as a Company we remain focused on human health, with the quality and benefits of EpiSwitch™ well recognised in immuno-oncology and neurodegenerative applications, this study demonstrates that there is a wider potential of our technology to ensure that the benefit of EpiSwitch™ is fully realised."

 

-ENDS-

 

For further details please contact:

 

Oxford BioDynamics Plc

Christian Hoyer Millar, CEO

Paul Stockdale, CFO

 

 

+44 (0)1865 518910

FTI Consulting

Financial Public Relations Adviser

Natalie Garland-Collins

+44 (0)20 3727 1000

 

Notes for Editors

 

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. 

 

The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 

 

In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

 

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

 

The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLFSVLSIELII
Date   Source Headline
11th Apr 202212:00 pmRNSHolding(s) in Company
8th Apr 202210:40 amRNSPDMR Dealing
7th Apr 202210:36 amRNSPDMR Dealing
6th Apr 20224:14 pmRNSPDMR Dealing
6th Apr 20224:03 pmRNSPDMR Dealing
30th Mar 20222:09 pmRNSResults of Annual General Meeting
4th Mar 20229:42 amRNSPDMR Dealing
3rd Mar 20229:58 amRNSPDMR Dealing
1st Mar 20224:16 pmRNSPUBLICATION OF 2021 ANNUAL REPORT
25th Feb 20227:00 amRNSUS launch of EpiSwitch® CiRT for oncology
15th Feb 202210:17 amRNSPDMR Dealing
10th Feb 202211:52 amRNSPDMR Dealing
8th Feb 20223:10 pmRNSHolding(s) in Company
7th Feb 20222:47 pmRNSPDMR Dealing
26th Jan 20229:50 amRNSPDMR Dealing
25th Jan 202211:44 amRNSPDMR Dealing
25th Jan 20227:00 amRNSFinal Results
19th Jan 20229:58 amRNSHolding(s) in Company
14th Jan 20222:36 pmRNSHolding(s) in Company
14th Jan 20227:00 amRNSHolding(s) in Company
13th Jan 202212:00 pmRNSHolding(s) in Company
11th Jan 20229:00 amRNSHolding(s) in Company
10th Jan 20227:02 amRNSHolding(s) in Company
4th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20214:00 pmRNSHolding(s) in Company
24th Dec 202111:40 amRNSPDMR Dealing
23rd Dec 20217:00 amRNSNotice of Results
17th Dec 20217:00 amRNSOBD updates on EpiSwitch CST and CiRT tests
13th Dec 20212:23 pmRNSHolding(s) in Company
13th Dec 202110:12 amRNSPDMR Dealing
1st Dec 202112:00 pmRNSPDMR Dealing
24th Nov 20213:02 pmRNSPDMR Dealing
22nd Nov 202111:00 amRNSPDMR Dealing
18th Nov 20213:16 pmRNSHolding(s) in Company
18th Nov 20213:10 pmRNSPDMR Dealing
18th Nov 202111:53 amRNSHolding(s) in Company
11th Nov 202111:08 amRNSResults of General Meeting
4th Nov 20217:00 amRNSHolding(s) in Company
2nd Nov 202112:22 pmRNSHolding(s) in Company
1st Nov 202112:43 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSHolding(s) in Company
25th Oct 20212:45 pmRNSOBD raises £3.62 million
6th Oct 20214:41 pmRNSSecond Price Monitoring Extn
6th Oct 20214:35 pmRNSPrice Monitoring Extension
28th Sep 20217:00 amRNSChange of Registered Office
31st Aug 20217:00 amRNSOxford BioDynamics awarded US FNIH Grant
15th Jun 20211:06 pmRNSPDMR Dealing
15th Jun 20217:00 amRNSHalf-year Report
27th May 20219:00 amRNSNotice of Results
14th May 202110:17 amRNSPDMR Dealing / Grant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.